Microbiome-based therapies have shown significant promise in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Research has identified specific psychobiotics that can produce neurotransmitters and influence brain function, and clinical trials are currently underway to investigate their use as therapeutic agents. By supporting research and development in this area, we can help to unlock the full potential of microbiome-based therapies and improve the lives of individuals affected by neurodegenerative diseases.

Gene editing technologies have the potential to revolutionize the treatment of rare genetic disorders. By providing a precise and efficient way to edit genes, these technologies can be used to develop novel therapies that are tailored to specific patient populations. This article explores the potential of gene editing technologies in developing novel therapies for rare genetic disorders, with a focus on emerging markets.